Do not stop or change your medication without speaking to a pharmacist or healthcare professional.

Health Canada safety review finds link between the use of Xeljanz and Xeljanz XR (tofacitinib) and increased risk of serious heart-related issues and cancer

Drugs · Last updated 2022-01-12

Why it was recalled

Product safety

Other Recent Recalls

Recall data is sourced from Health Canada's Recalls and Safety Alerts open dataset. MedShort.ca is an independent tracking tool and does not provide medical advice — for questions about this recall, contact the manufacturer or your pharmacist, or read the full notice linked above.